In contrast, the STEP-HFpEF [14,15] and SUMMIT [35] trials demonstrated robust, positive findings in patients with obesity-related HFpEF, populations more closely aligned with the metabolic targets of GLP-1 receptor agonists. This evidence concerns the gene GLP1R and Obesity.